In vitro and in vivo anti-tumor efficacy of CAR-iNKT cells has been demonstrated across many malignancies, with targets including CD19 for B-cell malignancies (62, 64, 84–86), BCMA (62, 63) or CD38 (63) for multiple myeloma, GD2 for neuroblastoma (87), TCRVβ for T-cell lymphoma (88), and B7H3 for multiple solid tumors (89). This evidence concerns the gene CD276 and neoplasm.